Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01ICY
|
|||
| Former ID |
DIB008664
|
|||
| Drug Name |
AVE-0657
|
|||
| Synonyms |
IDDBCP219683
Click to Show/Hide
|
|||
| Indication | Cheyne-stokes respiration [ICD-11: MD11.Y] | Phase 2 | [1] | |
| Company |
Sanofi
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/hydrogen exchanger 3 (SLC9A3) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Proximal tubule bicarbonate reclamation | |||
| Protein digestion and absorption | ||||
| Bile secretion | ||||
| Mineral absorption | ||||
| Pathway Interaction Database | Endothelins | |||
| RhoA signaling pathway | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00614250) Evaluation of the Effect of AVE0657 on Obstructive Sleep Apnea. U.S. National Institutes of Health. | |||
| REF 2 | Inhibition of central Na(+)/H(+) exchanger type 3 can alleviate sleep apnea in Sprague-Dawley rats. Chin Med J (Engl). 2014;127(1):48-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.